Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis.

MLA

Chiricozzi, A., et al. “Dupilumab-Associated Ocular Adverse Events Are Predicted by Low Tear Break-up Time and Correlate with High IL-33 Tear Concentrations in Patients with Atopic Dermatitis.” Experimental Dermatology, vol. 32, no. 9, Sept. 2023, pp. 1531–37. EBSCOhost, https://doi.org/10.1111/exd.14859.

APA

Chiricozzi, A., Di Nardo, L., Gori, N., Antonelli, F., Pinto, L., Cuffaro, G., Piro, G., Savino, G., Tortora, G., & Peris, K. (2023). Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis. Experimental Dermatology, 32(9), 1531–1537. https://doi.org/10.1111/exd.14859

Chicago

Chiricozzi, A, L Di Nardo, N Gori, F Antonelli, L Pinto, G Cuffaro, G Piro, G Savino, G Tortora, and K Peris. 2023. “Dupilumab-Associated Ocular Adverse Events Are Predicted by Low Tear Break-up Time and Correlate with High IL-33 Tear Concentrations in Patients with Atopic Dermatitis.” Experimental Dermatology 32 (9): 1531–37. doi:10.1111/exd.14859.